Held by 2 specialist biotech funds
**Signal Note: Eventide Initiates LIN Position** Eventide's $9.1M entry into Linde appears driven by industrial gas demand tailwinds in biotech manufacturing rather than a specific catalyst. Linde supplies critical inputs (cryogenic gases, specialty chemicals) for biopharmaceutical production, cell therapy scaling, and vaccine manufacturing—sectors aligned with Eventide's healthcare focus. The timing suggests conviction in sustained biotech capex and GMP manufacturing expansion, though the position size is modest relative to Eventide's $11B+ AUM.